pirfenidone (Deskar, Esbriet)
Jump to navigation
Jump to search
Indications
- treatment of idiopathic pulmonary fibrosis[1][2] (NICE)
* slows progression of disease on pulmonary function tests[3]
* does not elevate patients' perceived quality of life[3]
Contraindications
Dosage
Adverse effects
- nausea
- dizziness[2]
- rash
- fatigue
- diarrhea
- dyspepsia, abdominal pain
- photosensitivity, propensity to sunburn[2]
- upper respiratory tract infection
- headache
- anorexia
- GERD
- sinusitis
- insomnia
- weight loss
- arthralgia
Mechanism of action
- anti-fibrotic agent
More general terms
References
- ↑ 1.0 1.1 1.2 King TE et al A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. May 18, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24836312 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1402582
- ↑ 2.0 2.1 2.2 2.3 2.4 FDA News Release. October 15, 2014. FDA approves Esbriet to treat idiopathic pulmonary fibrosis. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm
- ↑ 3.0 3.1 3.2 Dempsey TM, Sangaralingham LR, Yao Xet al. Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2019 Jul 15; 200:168 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31150266 https://www.atsjournals.org/doi/10.1164/rccm.201902-0456OC